The news has made headlines everywhere: the first clinical trial using cells derived from human embryonic stem cells (hESC’s) has – finally – been approved by the FDA. And while there is a high level of excitement surrounding this truly groundbreaking move, there is also a palpable sense of trepidation among many in the neurology and neurosurgery communities…
Filed under: NerveCenter | Tagged: clinical trial, FDA, Geron, human embryonic stem cells, Myelination, phase 1 safety study, spinal cord injury, Tumorigenicity | Leave a Comment »
